Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Anti-Peripheral Nerve Myelin Antibodies and Terminal Activation Products of Complement in Serum of Patients With Acute Brachial Plexus Neuropathy

Anti-Peripheral Nerve Myelin Antibodies and Terminal Activation Products of Complement in Serum... Abstract Objective: To determine if complement-fixing antibodies to peripheral nerve myelin (anti-PNM antibodies) and terminal complement activation products were increased in serum of patients with brachial plexus neuropathy compared with normal controls. Design: Case series. Setting: University medical center. Patients: Three patients (aged 6, 39, and 51 years) with acute brachial plexus neuropathy were studied during the acute and recovery phase of their disease. Methods: Anti-PNM antibodies were measured in serum samples obtained from three patients and 25 normal controls with the Cl fixation and transfer assay. Soluble terminal complement activation products, SC5b-9, were measured by enzyme-linked immunosorbent assay (ELISA) in serum samples of one patient with brachial plexus neuropathy and of five normal controls. Results: Both serum anti-PNM antibodies and soluble terminal complement activation products were increased in the acute phase of brachial plexus neuropathy compared with normal control values and decreased several months later during clinical recovery. Conclusion: Complement dependent, antibodymediated demyelination may participate in the peripheral nerve damage of brachial plexus neuropathy. References 1. Tsairis P, Dyck PJ, Mulder DW. Natural history of brachial plexus neuropathy: report on 99 patients . Arch Neurol . 1972;27:109-117.Crossref 2. Windebank AJ. Inherited recurrent focal neuropathies . In: Dyck PJ, Thomas PK, Lambert EH, Burger R, eds. Peripheral Neuropathy . 2nd ed. Philadelphia, Pa: WB Saunders Co; 1984;1656-1670. 3. Koski CL, Gratz E, Sutherland J, Mayer RF. Clinical correlation with anti-peripheral nerve myelin antibodies in the Guillain-Barré syndrome . Ann Neurol . 1986;19:573-577.Crossref 4. Koski CL, Humphrey R, Shin ML. Anti-peripheral myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component 1 fixation . Proc Natl Acad Sci U S A . 1985; 82:905-909.Crossref 5. Vriesendorp FJ, Mayer RF, Koski CL. Kinetics of anti-peripheral nerve myelin antibody in patients with Guillain-Barré syndrome treated and not treated with plasmapheresis . Arch Neurol . 1991;48:858-861.Crossref 6. Koski CL, Sanders ME, Swoveland PT, et al. Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies . J Clin Invest . 1987;80:1492-1497.Crossref 7. Sawant-Mane S, Clark MB, Koski CL. In vitro demyelination by serum antibody from patients with Guillain-Barré syndrome requires terminal complement complexes . Ann Neurol . 1991;29:397-404.Crossref 8. Mayer MM, Michaels DW, Ramm LE, Whitlow MB, Willoughby JB, Shin ML. Membrane damage by complement CRC . Crit Rev Immunol . 1981;2:133-143. 9. Muller-Eberhard HJ. The membrane attack complex . Springer Semin Immunopathol . 1984;7:93-141.Crossref 10. Sano Y. Studies on the complement system in cerebrospinal fluid . Acta Med Univ Kagoshima . 1985;27:1-3. 11. Sanders ME, Koski CL, Robbins D, Shin ML, Frank MM, Joiner KA. Activated terminal complement in cerebrospinal fluid in Guillain-Barré multiple sclerosis . J Immunol . 1986;136:4456-4459. 12. Fearon DT. Activation of the alternative complement pathway . Crit Rev Immunol . 1979;1:1-11. 13. Pangburn MK. The Alternative Pathway in Immunobiology of the Complement System . Orlando, Fla: Academic Press Inc; 1986:45-59. 14. Koski CL, Vanguri P, Shin ML. Activation of the alternative pathway of complement by human peripheral nerve myelin . J Immunol . 1985;134:1810-1814. 15. Iqbal A, Arnason BGW. Neuropathy of serum sickness . In: Dyck PJ, Thomas PK, Lambert EH, Burger R, eds. Peripheral Neuropathy . 2nd ed. Philadelphia, Pa: WB Saunders Co; 1984:2044-2049. 16. Joffroy A. De la nevrite parenchymateuse spontane generalise ou partielle . Arch Physiol . 1879;6:172-175. 17. Flagman PD, Kelly JJ. Brachial plexus neuropathy: an electrophysiologic evaluation . Arch Neurol . 1980;37:160-164.Crossref 18. Subramony SH. AAEE case report 14: neuralgic amyotrophy (acute brachial neuropathy) . Muscle Nerve . 1988;11:39-44.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Neurology American Medical Association

Anti-Peripheral Nerve Myelin Antibodies and Terminal Activation Products of Complement in Serum of Patients With Acute Brachial Plexus Neuropathy

Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/anti-peripheral-nerve-myelin-antibodies-and-terminal-activation-8F8qJJUZ6e

References (20)

Publisher
American Medical Association
Copyright
Copyright © 1993 American Medical Association. All Rights Reserved.
ISSN
0003-9942
eISSN
1538-3687
DOI
10.1001/archneur.1993.00540120016006
Publisher site
See Article on Publisher Site

Abstract

Abstract Objective: To determine if complement-fixing antibodies to peripheral nerve myelin (anti-PNM antibodies) and terminal complement activation products were increased in serum of patients with brachial plexus neuropathy compared with normal controls. Design: Case series. Setting: University medical center. Patients: Three patients (aged 6, 39, and 51 years) with acute brachial plexus neuropathy were studied during the acute and recovery phase of their disease. Methods: Anti-PNM antibodies were measured in serum samples obtained from three patients and 25 normal controls with the Cl fixation and transfer assay. Soluble terminal complement activation products, SC5b-9, were measured by enzyme-linked immunosorbent assay (ELISA) in serum samples of one patient with brachial plexus neuropathy and of five normal controls. Results: Both serum anti-PNM antibodies and soluble terminal complement activation products were increased in the acute phase of brachial plexus neuropathy compared with normal control values and decreased several months later during clinical recovery. Conclusion: Complement dependent, antibodymediated demyelination may participate in the peripheral nerve damage of brachial plexus neuropathy. References 1. Tsairis P, Dyck PJ, Mulder DW. Natural history of brachial plexus neuropathy: report on 99 patients . Arch Neurol . 1972;27:109-117.Crossref 2. Windebank AJ. Inherited recurrent focal neuropathies . In: Dyck PJ, Thomas PK, Lambert EH, Burger R, eds. Peripheral Neuropathy . 2nd ed. Philadelphia, Pa: WB Saunders Co; 1984;1656-1670. 3. Koski CL, Gratz E, Sutherland J, Mayer RF. Clinical correlation with anti-peripheral nerve myelin antibodies in the Guillain-Barré syndrome . Ann Neurol . 1986;19:573-577.Crossref 4. Koski CL, Humphrey R, Shin ML. Anti-peripheral myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component 1 fixation . Proc Natl Acad Sci U S A . 1985; 82:905-909.Crossref 5. Vriesendorp FJ, Mayer RF, Koski CL. Kinetics of anti-peripheral nerve myelin antibody in patients with Guillain-Barré syndrome treated and not treated with plasmapheresis . Arch Neurol . 1991;48:858-861.Crossref 6. Koski CL, Sanders ME, Swoveland PT, et al. Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies . J Clin Invest . 1987;80:1492-1497.Crossref 7. Sawant-Mane S, Clark MB, Koski CL. In vitro demyelination by serum antibody from patients with Guillain-Barré syndrome requires terminal complement complexes . Ann Neurol . 1991;29:397-404.Crossref 8. Mayer MM, Michaels DW, Ramm LE, Whitlow MB, Willoughby JB, Shin ML. Membrane damage by complement CRC . Crit Rev Immunol . 1981;2:133-143. 9. Muller-Eberhard HJ. The membrane attack complex . Springer Semin Immunopathol . 1984;7:93-141.Crossref 10. Sano Y. Studies on the complement system in cerebrospinal fluid . Acta Med Univ Kagoshima . 1985;27:1-3. 11. Sanders ME, Koski CL, Robbins D, Shin ML, Frank MM, Joiner KA. Activated terminal complement in cerebrospinal fluid in Guillain-Barré multiple sclerosis . J Immunol . 1986;136:4456-4459. 12. Fearon DT. Activation of the alternative complement pathway . Crit Rev Immunol . 1979;1:1-11. 13. Pangburn MK. The Alternative Pathway in Immunobiology of the Complement System . Orlando, Fla: Academic Press Inc; 1986:45-59. 14. Koski CL, Vanguri P, Shin ML. Activation of the alternative pathway of complement by human peripheral nerve myelin . J Immunol . 1985;134:1810-1814. 15. Iqbal A, Arnason BGW. Neuropathy of serum sickness . In: Dyck PJ, Thomas PK, Lambert EH, Burger R, eds. Peripheral Neuropathy . 2nd ed. Philadelphia, Pa: WB Saunders Co; 1984:2044-2049. 16. Joffroy A. De la nevrite parenchymateuse spontane generalise ou partielle . Arch Physiol . 1879;6:172-175. 17. Flagman PD, Kelly JJ. Brachial plexus neuropathy: an electrophysiologic evaluation . Arch Neurol . 1980;37:160-164.Crossref 18. Subramony SH. AAEE case report 14: neuralgic amyotrophy (acute brachial neuropathy) . Muscle Nerve . 1988;11:39-44.Crossref

Journal

Archives of Neurology – American Medical Association

Published: Dec 1, 1993

There are no references for this article.